Published in Antimicrob Agents Chemother on December 01, 2004
Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev (2009) 5.76
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother (2010) 2.16
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother (2007) 2.04
Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev (2012) 1.84
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.69
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2009) 1.55
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother (2011) 1.54
The accessory genome of Pseudomonas aeruginosa. Microbiol Mol Biol Rev (2010) 1.53
Four genotyping schemes for phylogenetic analysis of Pseudomonas aeruginosa: comparison of their congruence with multi-locus sequence typing. PLoS One (2013) 1.52
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res (2010) 1.52
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother (2008) 1.51
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother (2011) 1.50
Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One (2011) 1.48
Polyamines induce resistance to cationic peptide, aminoglycoside, and quinolone antibiotics in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2006) 1.33
Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care (2014) 1.26
Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control (2014) 1.20
Antimicrobial resistance in hospitals: how concerned should we be? CMAJ (2009) 1.16
The regulatory repertoire of Pseudomonas aeruginosa AmpC ß-lactamase regulator AmpR includes virulence genes. PLoS One (2012) 1.14
Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother (2012) 1.13
Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int J Biol Sci (2010) 1.10
VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg Infect Dis (2012) 1.09
Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother (2005) 1.07
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.06
Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India. J Pharmacol Pharmacother (2011) 1.05
Characterization of the core and accessory genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt. BMC Genomics (2014) 1.05
Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother (2006) 1.03
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med (2010) 1.00
Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance. Curr Microbiol (2011) 0.98
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother (2006) 0.93
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother (2011) 0.90
Assessment of Pseudomonas aeruginosa N5,N10-methylenetetrahydrofolate dehydrogenase-cyclohydrolase as a potential antibacterial drug target. PLoS One (2012) 0.87
Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone. Genome Announc (2013) 0.87
Biochemical characterization of malate synthase G of P. aeruginosa. BMC Biochem (2009) 0.86
Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital. J Clin Diagn Res (2013) 0.83
Cytotoxicity of Pseudomonas secreted exotoxins requires OxyR expression. J Surg Res (2007) 0.82
Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand. Ann Clin Microbiol Antimicrob (2012) 0.80
Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation. Infect Control Hosp Epidemiol (2012) 0.80
Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India. Indian J Pharmacol (2008) 0.80
Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect (2016) 0.79
Possible Role of Curcumin as an Efflux Pump Inhibitor in Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa. J Clin Diagn Res (2014) 0.79
Survival of Antibiotic Resistant Bacteria and Horizontal Gene Transfer Control Antibiotic Resistance Gene Content in Anaerobic Digesters. Front Microbiol (2016) 0.78
Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. Infect Dis Ther (2016) 0.78
Bacterial Isolates and Their Antimicrobial Susceptibility Patterns of Wound Infections among Inpatients and Outpatients Attending the University of Gondar Referral Hospital, Northwest Ethiopia. Int J Microbiol (2017) 0.78
Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide. J Infect Dis (2015) 0.77
Identification of MupP as a New Peptidoglycan Recycling Factor and Antibiotic Resistance Determinant in Pseudomonas aeruginosa. MBio (2017) 0.77
Antibiotic synergy interaction against multidrug-resistant Pseudomonas aeruginosa isolated from an abattoir effluent environment. ScientificWorldJournal (2012) 0.77
In vitro evaluation of novel compounds against selected resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother (2011) 0.77
Incidence of Multidrug-Resistant Pseudomonas Spp. in ICU Patients with Special Reference to ESBL, AMPC, MBL and Biofilm Production. J Glob Infect Dis (2016) 0.76
Transcriptome Profiling of Antimicrobial Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2016) 0.76
Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain. Genome Announc (2014) 0.76
Solution structure and properties of AlgH from Pseudomonas aeruginosa. Proteins (2015) 0.75
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis (2017) 0.75
Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy. Antibiotics (Basel) (2015) 0.75
Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital. Infect Drug Resist (2015) 0.75
Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals. Can J Infect Dis Med Microbiol (2011) 0.75
Antibacterial Activity of Hibicuslide C on Multidrug-Resistant Pseudomonas aeruginosa Isolates. Curr Microbiol (2016) 0.75
Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder. Spinal Cord Ser Cases (2017) 0.75
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 9.51
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 7.40
The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol (1985) 6.94
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med (1998) 4.48
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. Am J Infect Control (1999) 4.30
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA (2003) 4.09
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.86
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med (1996) 2.72
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA (1999) 2.16
Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis (1996) 2.03
Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother (2004) 1.70
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis (2001) 1.22
Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm (2013) 5.02
Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy (2005) 2.11
Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis (2003) 1.74
A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med (2014) 1.66
Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) (2013) 1.60
Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother (2009) 1.47
Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother (2002) 1.31
Patient-level medication regimen complexity across populations with chronic disease. Clin Ther (2013) 1.24
Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy (2002) 1.11
Pharmacist contributions as members of the multidisciplinary ICU team. Chest (2013) 1.08
Stability of phenylephrine hydrochloride injection in polypropylene syringes. Am J Health Syst Pharm (2007) 0.99
Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy (2006) 0.96
Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother (2002) 0.95
Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol (2008) 0.94
Fospropofol: a new sedative-hypnotic agent for monitored anesthesia care. Ann Pharmacother (2009) 0.93
Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother (2006) 0.92
Risk factors for acute kidney injury in adult patients receiving vancomycin. Clin Drug Investig (2014) 0.91
Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant (2005) 0.89
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy (2005) 0.88
Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. Ann Pharmacother (2009) 0.87
Enteral glutamine supplementation in critically ill patients with burn injuries: a retrospective case-control evaluation. Pharmacotherapy (2007) 0.87
Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. JPEN J Parenter Enteral Nutr (2008) 0.86
Pulsed-field gel electrophoresis genotyping of Salmonella gallinarum and comparison with random amplified polymorphic DNA. Vet Microbiol (2006) 0.86
A multifaceted intervention to implement guidelines did not affect hospitalization rates for nursing home-acquired pneumonia. J Am Med Dir Assoc (2010) 0.84
Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr (2007) 0.84
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother (2004) 0.84
Vitreous penetration of orally administered famciclovir. Am J Ophthalmol (2009) 0.84
Impact of a multidisciplinary intervention on antibiotic use for nursing home-acquired pneumonia. Am J Geriatr Pharmacother (2011) 0.83
Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Drugs R D (2002) 0.82
Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci (2005) 0.82
Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy (2010) 0.82
Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy (2014) 0.81
Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy (2002) 0.81
Implementing and assessing an evidence-based electrolyte dosing order form in the medical ICU. Intensive Crit Care Nurs (2007) 0.80
In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2002) 0.80
Treatment of hepatorenal syndrome. Pharmacotherapy (2009) 0.80
In vitro bactericidal activity of piperacillin, gentamicin, and metronidazole in a mixed model containing Escherichia coli, Enterococcus faecalis, and Bacteroides fragilis. Diagn Microbiol Infect Dis (2002) 0.80
Thermoresponsive fluconazole gels for topical delivery: rheological and mechanical properties, in vitro drug release and anti-fungal efficacy. Pharm Dev Technol (2013) 0.78
Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol (2002) 0.78
Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). Am J Health Syst Pharm (2010) 0.78
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy (2013) 0.78
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant (2014) 0.77
The role of vasopressin in vasodilatory septic shock. Pharmacotherapy (2004) 0.77
Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother (2004) 0.77
Polymorphism of pertactin gene repeat regions in Bordetella bronchiseptica isolates from pigs. J Vet Med Sci (2007) 0.77
Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. J Heart Lung Transplant (2012) 0.77
Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy (2010) 0.76
Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis (2002) 0.76
Bronchoscopic sampling of drug concentrations: penetration to tissue is the issue. Am J Respir Crit Care Med (2003) 0.75
Nebulized oil-in-water nanoemulsion mists for pulmonary delivery: development, physico-chemical characterization and in vitro evaluation. Drug Dev Ind Pharm (2013) 0.75
Anidulafungin and its role in candida infections. Infect Drug Resist (2009) 0.75
Telithromycin: do we really need this antimicrobial? Am J Health Syst Pharm (2005) 0.75
Octreotide: a drug often used in the critical care setting but not well understood. Chest (2013) 0.75
Stability of dexmedetomidine in polyvinyl chloride bags containing 0.9% sodium chloride injection. Am J Health Syst Pharm (2013) 0.75
In vitro bactericidal activity of ABT-773 versus four other agents against Streptococcus pneumoniae and Haemophilus influenzae. Int J Antimicrob Agents (2002) 0.75
595: PERIOPERATIVE 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FACTOR VIIA IN LIVER TRANSPLANTATION. Crit Care Med (2016) 0.75
Molecular typing by random amplification of polymorphic DNA (RAPD) and detection of virulence genes of Salmonella enterica subspecies enterica serovar Gallinarum biovar gallinarum. J Vet Med Sci (2006) 0.75
Gastrointestinal hormone concentrations associated with gastric feeding in critically ill patients. JPEN J Parenter Enteral Nutr (2011) 0.75
Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). Pharmacotherapy (2002) 0.75
Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings. Am J Health Syst Pharm (2007) 0.75
Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother (2008) 0.75
Neuromuscular blockade resistance during therapeutic hypothermia. Ann Pharmacother (2011) 0.75
1843: LEVETIRACETAM PHARMACOKINETICS IN A PATIENT WITH INTRACRANIAL HEMORRHAGE UNDERGOING CVVH. Crit Care Med (2016) 0.75
The Aurora theater shooting: lessons learned in a department of pharmacy. Am J Health Syst Pharm (2014) 0.75
Development and characterization of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery. Drug Dev Ind Pharm (2014) 0.75
Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother (2009) 0.75
704: PHARMACOKINETIC EVALUATION OF CONTINUOUS AND EXTENDED-INFUSION ANTIBIOTICS IN BURN PATIENTS. Crit Care Med (2016) 0.75
Preparation, characterization, sterility validation, and in vitro cell toxicity studies of microemulsions possessing potential parenteral applications. Drug Dev Ind Pharm (2012) 0.75
Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opin Drug Saf (2014) 0.75
Development and characterization of nanostructured mists with potential for actively targeting poorly water-soluble compounds into the lungs. Pharm Res (2013) 0.75